comparemela.com

Onclive Institutional Perspectives News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Cobain on Future Considerations For the Treatment of HR+/HER2– Breast Cancer

Erin Frances Cobain, MD, discusses key takeaways from an OncLive Institutional Perspectives in Cancer webinar on breast cancer.

United statesErin frances cobainUniversity of michiganRogel cancer centerBreast cancer clinical research teamOnclive institutional perspectives

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.

Margaret gatti maysErin frances cobainMonika burnessBreast cancer clinical research teamAlliance for clinical trials in oncologyUniversity of michigan rogel cancer centerOnclive institutional perspectivesMichigan rogel cancer centerAnn arborClinical trialsEarly stage breast cancerTriple negative breast cancer

The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations

Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.

United statesSan antonioAnn arborErin frances cobainAmerican society of clinical oncology annual meetingUniversity of michigan rogel cancer centerUniversity of michiganBreast cancer clinical research teamOnclive institutional perspectivesMichigan rogel cancer centerSan antonio breast cancer symposiumAmerican societyClinical oncology annual

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

United statesUniversity of california irvineCatherinec coombsNiravn shahSwetha kambhampatiDepartment of medicineCollege of wisconsinDivision of hematologySchool of medicineCalifornia irvineOnclive institutional perspectivesMedical collegeMantle cell lymphomaLargeb cell lymphomaBispecific antibodies

SOC Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

United statesCatherinec coombsAngelag fleischmannNaveen pemmarajuJoshuaf zeidnerInternational consensus classificationSchool of medicineDivision of hematologyDepartment of medicineWorld health organizationUniversity of california irvineOnclive institutional perspectivesCalifornia irvineNew england journalChapel hillInternational consensus

vimarsana © 2020. All Rights Reserved.